Caribou Biosciences Stock Plunges 40% on Halt of CAR-T Programs

3-line summary

• Caribou Biosciences stock plunged 40% after the company halted its CAR-T programs, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.